Suppr超能文献

南澳大利亚州苯丙胺衍生物致死事件——“摇头丸”是罪魁祸首吗?

Amphetamine derivative fatalities in South Australia--is "Ecstasy" the culprit?

作者信息

Byard R W, Gilbert J, James R, Lokan R J

机构信息

Forensic Science, Adelaide, South Australia, Australia.

出版信息

Am J Forensic Med Pathol. 1998 Sep;19(3):261-5. doi: 10.1097/00000433-199809000-00013.

Abstract

OBJECTIVE

To analyze features of a series of fatalities caused by amphetamine-derivative designer drugs marketed as "Ecstasy" in South Australia, and to identify reasons for the recent marked increase in number of these deaths.

MATERIALS AND METHODS

Following the death of a 26-year-old woman after alleged ingestion of Ecstasy tablets, a retrospective search of files at State Forensic Science, Adelaide and the South Australian State Coroner's Department was undertaken from February 1992 to January 1997 to identify similar cases.

RESULTS

Six fatalities were found, all of which have occurred since September 1995 (M:F ratio, 1:1; age range, 22 to 36 years; average age, 27.7 years). All individuals had histories of recent ingestion of illegal drugs thought to be Ecstasy (methylenedioxymethamphetamine, MDMA) at the time of purchase. Delay occurred in seeking medical attention, despite severe symptoms. Causes of death involved documented hyperthermia in 3 cases (temperatures of 41.5-46.1 degrees C), with features of hyperthermia in one other case, and intracranial hemorrhage in another. Drugs in toxic/lethal amounts identified at postmortem included paramethoxyamphetamine (PMA) in all cases, amphetamine/methamphetamine in 4 cases, and methylenedioxymethamphetamine (MDMA or Ecstasy) in only 2 cases. Interaction with a prescription medication (fluoxetine) may have occurred in 1 case.

CONCLUSIONS

The number of deaths due to amphetamine derivatives apparently due to substitution of PMA for MDMA (Ecstasy) have recently increased markedly in Adelaide. Potential users should be warned that PMA has been associated with a much higher rate of lethal complications than other designer drugs, and that no guarantee can be made that tablets sold as Ecstasy are not PMA.

摘要

目的

分析在南澳大利亚作为“摇头丸”销售的苯丙胺类新型毒品导致的一系列死亡案例的特征,并找出近期此类死亡人数显著增加的原因。

材料与方法

在一名26岁女性据称服用摇头丸片剂后死亡后,对阿德莱德州法医科学中心和南澳大利亚州验尸官部门1992年2月至1997年1月的档案进行回顾性检索,以确定类似案例。

结果

共发现6例死亡案例,均发生于1995年9月以后(男女比例为1:1;年龄范围为22至36岁;平均年龄为27.7岁)。所有个体在购买时均有近期摄入被认为是摇头丸(亚甲二氧基甲基苯丙胺,MDMA)的非法药物史。尽管症状严重,但就医延迟。死亡原因包括3例有记录的体温过高(体温为41.5 - 46.1摄氏度),1例有体温过高特征,另1例为颅内出血。尸检时确定的有毒/致死量药物包括所有案例中的对甲氧基苯丙胺(PMA),4例中的苯丙胺/甲基苯丙胺,仅2例中的亚甲二氧基甲基苯丙胺(MDMA或摇头丸)。1例可能与处方药(氟西汀)发生了相互作用。

结论

在阿德莱德,因用PMA替代MDMA(摇头丸)导致的苯丙胺类衍生物死亡人数近期显著增加。应警告潜在使用者,PMA与比其他新型毒品更高的致死并发症发生率相关,且无法保证作为摇头丸出售的片剂不是PMA。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验